- Home
- HRMY vs CSGS Comparison
HRMY vs CSGS Comparison
Compare HRMY & CSGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- CSGS
- Stock Information
- Founded
- HRMY 2017
- CSGS 1994
- Country
- HRMY United States
- CSGS United States
- Employees
- HRMY N/A
- CSGS N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- CSGS EDP Services
- Sector
- HRMY Health Care
- CSGS Technology
- Exchange
- HRMY Nasdaq
- CSGS Nasdaq
- Market Cap
- HRMY 2.1B
- CSGS 1.9B
- IPO Year
- HRMY 2020
- CSGS 1996
- Fundamental
- Price
- HRMY $35.99
- CSGS $64.81
- Analyst Decision
- HRMY Strong Buy
- CSGS Buy
- Analyst Count
- HRMY 9
- CSGS 8
- Target Price
- HRMY $55.33
- CSGS $68.86
- AVG Volume (30 Days)
- HRMY 531.4K
- CSGS 236.0K
- Earning Date
- HRMY 10-28-2025
- CSGS 11-05-2025
- Dividend Yield
- HRMY N/A
- CSGS 1.98%
- EPS Growth
- HRMY 58.41
- CSGS 30.24
- EPS
- HRMY 3.10
- CSGS 2.89
- Revenue
- HRMY $772,527,000.00
- CSGS $1,208,376,000.00
- Revenue This Year
- HRMY $20.09
- CSGS $3.49
- Revenue Next Year
- HRMY $16.74
- CSGS $3.23
- P/E Ratio
- HRMY $11.61
- CSGS $22.41
- Revenue Growth
- HRMY 17.74
- CSGS 3.31
- 52 Week Low
- HRMY $26.47
- CSGS $44.57
- 52 Week High
- HRMY $41.61
- CSGS $67.60
- Technical
- Relative Strength Index (RSI)
- HRMY 47.09
- CSGS 58.65
- Support Level
- HRMY $36.50
- CSGS $63.22
- Resistance Level
- HRMY $38.28
- CSGS $64.56
- Average True Range (ATR)
- HRMY 0.95
- CSGS 1.15
- MACD
- HRMY -0.17
- CSGS 0.25
- Stochastic Oscillator
- HRMY 9.84
- CSGS 78.62
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About CSGS CSG Systems International Inc.
CSG Systems International Inc is a purpose-driven, SaaS platform company that enables companies in a wide variety of industry verticals to tackle the growing complexity of business in the digital age. The company's cloud-first architecture and customer-centric approach empower companies to deliver unforgettable experiences for B2B (business-to-business), B2C (business-to-consumer), and B2B2X (business-to-business-to-consumer) customers, making it easier for people and businesses to connect to, use and pay for the services the company offers. The company operates in one segment i.e. Solutions and Services. Geographically, the company generates revenue from the United States.